Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
TSC1 regulates the balance between effector and regulatory T cells
Yoon Park, … , Mitchell Kronenberg, Yun-Cai Liu
Yoon Park, … , Mitchell Kronenberg, Yun-Cai Liu
Published November 25, 2013
Citation Information: J Clin Invest. 2013;123(12):5165-5178. https://doi.org/10.1172/JCI69751.
View: Text | PDF
Research Article

TSC1 regulates the balance between effector and regulatory T cells

  • Text
  • PDF
Abstract

Mammalian target of rapamycin (mTOR) plays a crucial role in the control of T cell fate determination; however, the precise regulatory mechanism of the mTOR pathway is not fully understood. We found that T cell–specific deletion of the gene encoding tuberous sclerosis 1 (TSC1), an upstream negative regulator of mTOR, resulted in augmented Th1 and Th17 differentiation and led to severe intestinal inflammation in a colitis model. Conditional Tsc1 deletion in Tregs impaired their suppressive activity and expression of the Treg marker Foxp3 and resulted in increased IL-17 production under inflammatory conditions. A fate-mapping study revealed that Tsc1-null Tregs that lost Foxp3 expression gained a stronger effector-like phenotype compared with Tsc1–/– Foxp3+ Tregs. Elevated IL-17 production in Tsc1–/– Treg cells was reversed by in vivo knockdown of the mTOR target S6K1. Moreover, IL-17 production was enhanced by Treg-specific double deletion of Tsc1 and Foxo3a. Collectively, these studies suggest that TSC1 acts as an important checkpoint for maintaining immune homeostasis by regulating cell fate determination.

Authors

Yoon Park, Hyung-Seung Jin, Justine Lopez, Chris Elly, Gisen Kim, Masako Murai, Mitchell Kronenberg, Yun-Cai Liu

×

Figure 5

TSC1-deficient Foxp3+ Treg cells produce IL-17 and convert into effector-like T cells.

Options: View larger image (or click on image) Download as PowerPoint
TSC1-deficient Foxp3+ Treg cells produce IL-17 and convert into effector...
(A) Flow cytometric analysis of IL-17A–producing CD45.2+CD4+ Treg cells from cLP of recipient mice as in Figure 4D, 6 weeks after transfer, followed by restimulation with PMA/ionomycin for 6 hours. (B) Flow cytometric analysis of YFP and RFP expression in CD4+ T cells (upper panel) or Foxp3 expression in CD4+RFP+ T cells (lower panel) in Foxp3YFPCreR26RFPTsc1+/+ and Foxp3YFPCreR26RFPTsc1f/f mice. (C) Immunoblot analysis of TSC1 in sorted CD4+RFP–YFP–, CD4+RFP+YFP–, and CD4+RFP+YFP+ T cells from Foxp3YFPCreR26RFPTsc1+/+ and Foxp3YFPCreR26RFPTsc1f/f mice. (D and E) Sorted CD4+RFP+YFP+ Treg cells (D, right panel) or CD4+RFP+YFP– ex-Treg cells (D, left panel), or CD4+CD62L+RFP–YFP– naive T cells (E) from Foxp3YFPCreR26RFPTsc1+/+ and Foxp3YFPCreR26RFPTsc1f/f mice were stimulated with anti-CD3/CD28 for 36 hours. Cytokine production was measured by Bio-Plex multicytokine assay. (F) Sorted CD4+RFP+YFP+ Treg cells were stimulated with anti-CD3/CD28, IL-2, and the indicated cytokines for 48 hours. Cytokine production was measured by Bio-Plex multicytokine assay. (G and H) Rag1–/– mice were given sorted CD4+RFP+YFP+ (CD45.2+) Treg cells from Foxp3YFPCreR26RFPTsc1+/+ or Foxp3YFPCreR26RFPTsc1f/f mice, together with CD4+CD45RBhi (CD45.1+) T cells. Flow cytometric analysis of RFP and YFP expression (G) or cytokine production (H) in CD45.2+CD4+RFP+ T cells of the recipient mice 6 weeks after transfer. Data are representative of (A, B, G, and H) or compiled from (D–F) two to five independent experiments. Error bars indicate the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by two-tailed, unpaired Student’s t test.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts